BIONTECH SE SPON. ADRS 1
Commented by Mario Hose on January 14th, 2022 | 12:17 CET
Natural active ingredient against Covid-19: BioNTech, Cardiol, Novavax, Valneva in focus
At the end of the week, trading on the German stock exchanges has been rather slow so far. The German leading index DAX is quoted at a level of 15,922 points and thus around 0.01% up. The index of the second tier, MDAX, traded last at 34,626 points (-0.11%), TecDAX at 3,537 points (-0.67%) and SDAX at 15,904 points with 0.43% in the red. A study from the U.S. will influence the future development of vaccine manufacturers in connection with Covid-19, according to initial research.
Read
Commented by Stefan Feulner on January 14th, 2022 | 11:44 CET
BioNTech, Defence Therapeutics, PAION - Seizing the momentum
The Corona pandemic brought biotechnology to the forefront of society's consciousness, especially since the first vaccines were created in German laboratories. However, the biotech spectrum is much broader than pandemic vaccine research. In addition to research in medicine, the sector is playing an increasingly important role in environmental protection, agriculture and the ongoing climate change.
Read
Commented by Mario Hose on January 13th, 2022 | 18:11 CET
New research results for Covid-19: BioNTech, Cardiol, Valneva
In the afternoon of today's trading day, the German indices extended the price losses in part after a brief recovery phase. The DAX is currently trading at 15,963 points, down around 0.41%. The psychological mark of 16,000 points was exceeded at midday in phases by more than 75 points. The MDAX last traded at 34,708 points (-0.62%), TecDAX at 3,577 points (-2.26%) and SDAX at 15,976 points with 0.66% in the red. New research results for the treatment and prevention of Covid-19 provide an exciting perspective for investors.
Read
Commented by Mario Hose on January 12th, 2022 | 10:53 CET
Trading stocks after EMA warning in focus: BioNTech, Johnson + Johnson, Moderna
On Wednesday, the German indices began with a positive sign. The German benchmark index DAX is currently quoted at a level of 16,004 points and thus around 0.04% slightly up. The companies in the second tier can also hold their ground and the MDAX last traded at 34,864 points (+0.26%), TexDAX at 3,644 points and thus 0.60% lower than the previous day. SDAX also loses and last traded at 15,969 points (-0.23%).
Read
Commented by Mario Hose on January 11th, 2022 | 11:36 CET
Trading stocks in focus: BioNTech, Darktrace, EXMceuticals
Tuesday is under a good omen on the stock market after a failed start to the week. Germany's leading index, the DAX, is trading at 15,961 points, up around 0.32%, but has not yet made it above the psychological 16,000 mark. The MDAX last traded at 34,713 points (+0.42%), TexDAX at 3,661 points (+1.09%) and SDAX at 15,913 points with 0.66% in the plus.
Read
Commented by Mario Hose on January 10th, 2022 | 12:02 CET
Trading stocks in focus: Aspermont, BASF, BioNTech
At the beginning of the week, the DAX is currently trading around 0.19% down at 15,939 points and thus remains below the psychological mark of 16,000 points. The MDAX recently traded again below the 35,000 mark at 34,804 points (-0.52%), TexDAX at 3,653 points (-1.50%) and SDAX at 15,936 points with 1.06% in the red. Overall, the indices had given back their initial gains from the start of trading and are trading in negative territory in the morning.
Read
Commented by André Will-Laudien on January 10th, 2022 | 10:22 CET
Tembo Gold, BioNTech, Valneva, MorphoSys - Turnaround or crash?
At the beginning of the year, there is much talk about the seemingly eternally running stock markets and the infinite wealth of those who have done everything right. Of course, shorting Tesla was a risk; it went wrong 85% of the time. However, since the "minutes" of the Federal Reserve, it is perhaps not a new short with the announcement. Because interest rates will probably have to rise once the tapering gets going. Incidentally, opinions are divided on the inflation trend: some banks estimate a 1 before the decimal point, others see a 5. So what now? Interest rates up mean problems for growth stocks; interest rates down could mean a continuation of the bull market. We take a look at interesting shares with their own stories.
Read
Commented by Mario Hose on January 7th, 2022 | 16:04 CET
Trading shares in focus: Allianz, BioNTech, BrainChip
At the end of the week, the DAX was down around 0.37% at 15,968 points and thus below the psychological mark of 16,000 points. The MDAX last traded at 35,002 points (-34%), TexDAX at 3,731 points (-0.36%) and SDAX at 16,125 points with 0.92% in the red.
Read
Commented by Nico Popp on January 7th, 2022 | 12:51 CET
BioNTech, XPhyto, Valneva: 3 stocks for next week?
Omicron is slowly but surely making its presence felt in Germany. After the holidays, when first there is less testing, and secondly the fax machines in German health offices are at a standstill, the official statistics are becoming a little more accurate again. There are already signs of where the journey might be headed. If the past week's growth remains constant, the incidence could already be above the 500 mark in 7 to 10 days. Although such projections are subject to error, it is worth looking at the typical pandemic stocks.
Read
Commented by Fabian Lorenz on January 6th, 2022 | 11:26 CET
The beginning of the end at BioNTech? Positive start for JinkoSolar and Diamcor
Is Omicron the beginning of the end of the Corona pandemic? Not only stock market players are asking themselves this question. Because as it seems, the virus variant is more contagious but seemingly leads to less severe sickness. As a result, the shares of vaccine manufacturers such as BioNTech, Moderna and Valneva have recently suffered. However, there are positive things to report, especially for BioNTech. While the Mainz-based Company is optimizing its vaccine for the Omicron variant, there is also positive news from the USA. Not only the COVID-19 vaccine is in demand worldwide, but also diamonds. Most recently, Israel reported a significant increase in demand. Tiffany & Co. partner Diamcor is benefiting from this demand. JinkoSolar's share price is heading north again in the first few days of trading after the heavy losses before Christmas. The IPO of the subsidiary is taking shape.
Read